Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 (Q54409668)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 |
scientific article |
Statements
Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 (English)
Carlos Caldas
1 reference
Jean Abraham
Anne-Laure Vallier
Louise Hiller
Nicola Fenwick
Jennie Young
Mahesh Iddawela
Luke Hughes-Davies
Ioannis Gounaris
Karen McAdam
Stephen Houston
Anthony Skene
Susan Dean
Diana Ritchie
Robert Laing
Mark Harries
Christopher Gallagher
Gordon Wishart
Elena Provenzano
Neo-tAnGo Investigators
19 December 2013
15
2
201-212